Therapeutic drug monitoring in patients with inflammatory bowel disease.

Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease. Mediators Inflamm (2014) 0.92

Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1. J Biol Chem (2014) 0.78

The Importance of Intestinal Eotaxin-1 in Inflammatory Bowel Disease: New Insights and Possible Therapeutic Implications. Dig Dis Sci (2016) 0.77

Role of Allopurinol in Optimizing Thiopurine Therapy in Patients with Autoimmune Hepatitis: A Review. J Clin Exp Hepatol (2017) 0.75

Impact of Specialized Inpatient IBD Care on Outcomes of IBD Hospitalizations: A Cohort Study. Inflamm Bowel Dis (2016) 0.75

Insights on the use of biosimilars in the treatment of inflammatory bowel disease. World J Gastroenterol (2017) 0.75

The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience. Can J Gastroenterol Hepatol (2016) 0.75

Xanthine Oxidoreductase in Drug Metabolism: Beyond a Role as a Detoxifying Enzyme. Curr Med Chem (2016) 0.75

A Personalized Approach to Managing Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y) (2016) 0.75

Pharmacogenetics in inflammatory bowel disease: understanding treatment response and personalizing therapeutic strategies. Pharmgenomics Pers Med (2017) 0.75

Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14

Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35

Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med (2003) 8.49

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 6.36

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut (2011) 6.08

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut (2010) 4.50

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut (2007) 4.21

Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut (2013) 3.49

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology (2000) 2.99

Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut (2011) 2.87

Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol (2007) 2.77

Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.65

Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol (2010) 2.55

6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology (2002) 2.35

A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol (2013) 2.31

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol (2008) 2.15

Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology (2006) 2.14

Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology (2005) 2.05

Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 2.04

Retracted A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity. Am J Gastroenterol (2008) 2.04

Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology (2009) 2.00

Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther (2005) 1.79

Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2007) 1.75

Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol (2012) 1.66

Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol (2013) 1.61

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther (2009) 1.54

Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. Aliment Pharmacol Ther (2011) 1.53

Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit (2008) 1.42

Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol (2005) 1.36

Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs (2010) 1.26

Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol (2013) 1.26

Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther (2008) 1.14

Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut (2001) 1.12

Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut (2001) 1.11

Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther (2011) 1.11

Molecular analysis of thiopurine S-methyltransferase alleles in South-east Asian populations. Pharmacogenetics (2002) 1.01

Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol (1998) 1.00

Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism. Aliment Pharmacol Ther (2012) 0.99

Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay. J Pharm Biomed Anal (2013) 0.99

High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment. J Crohns Colitis (2013) 0.92

Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines. J Pharmacol Exp Ther (2004) 0.90

C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease. J Gastroenterol (2013) 0.90

The impact of biologics on health-related quality of life in patients with inflammatory bowel disease. Clin Exp Gastroenterol (2009) 0.89

A SPECIAL MEETING REVIEW EDITION: Clinical Research Highlights in IBD: Diagnosis and Anti-Tumor Necrosis Factor Monitoring: Digestive Disease Week 2013May 18-21, 2013 • Orlando, FloridaSpecial Reporting on:• Serological and Inflammatory IBD Marker Prevalence As Function of Age in a Large Cohort of Patients Presenting IBD-Like Gastrointestinal Symptoms• Prevalence of Antibodies to Adalimumab (ATA) and Correlation Between ATA and Low Serum Drug Concentration on CRP and Clinical Symptoms in a Prospective Sample of IBD Patients• Serum Adalimumab Levels and Antibodies Correlate with Endoscopic Intestinal Inflammation and Inflammatory Markers in Patients with Inflammatory Bowel Disease• Comparison of Early Measurement of Infliximab and Antibodies-to-Infliximab Serum Levels with Standard Trough Analysis• Trough Levels and Antidrug Antibodies Predict Safety and Success of Restarting Infliximab After a Long Drug Holiday• A Multi-Center Observational Study in Community Gastroenterology Practices Evaluating the Clinical Usage of Testing for Serum Levels of Infliximab and Antibodies to Infliximab• Preoperative Serum Biologic Levels Do Not Impact Postoperative Outcomes in Ulcerative Colitis• Higher Preoperative Serum Biologic Levels Are Associated with Postoperative Complications in Crohn's Disease PatientsWith Expert Commentary by: William J. Sandborn, MDProfessor and Chief, Division of GastroenterologyDirector, UCSD IBD CenterUC San Diego Health SystemLa Jolla, California. Gastroenterol Hepatol (N Y) (2013) 0.89

Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut (2004) 0.88

Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients. Am J Gastroenterol (2007) 0.88

Methylation of 6-mercaptopurine and 6-thioguanine by thiopurine S-methyltransferase. A comparison of activity in red blood cell samples of 199 blood donors. Eur J Clin Pharmacol (2000) 0.85

Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide. Eur J Clin Pharmacol (1996) 0.84

Human thiopurine S-methyltransferase activity in uremia and after renal transplantation. Eur J Clin Pharmacol (2001) 0.77